Clinical Trials
5 trialsNCT06627647 2026-05-22
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC
AstraZeneca
Phase 3 Recruiting
NCT06868836 2026-05-18
Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
NCT07264816 2026-03-05
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2 Recruiting
NCT07178795 2025-11-17
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT05245071 2025-08-29
CARMEN-LC06
Sanofi
Phase 2 Terminated